“Having the SRT-100 Vision system at Sheba Medical Center, the largest hospital in the country and a significant member of the global medical community, furthers Sensus’s mission to make this breakthrough treatment available around the world,” said Joe Sardano, CEO of Sensus Healthcare.
The SRT-100 Vision system evaluates basal and squamous cell carcinomas and keloid tissue with targeted and precise treatment. Also, the LesionCam records each session, which enables doctors to closely track any changes in the lesion and customize treatment accordingly.
Sensus recently opened a new office in Tel Aviv – thereby expanding its footprint in the region. As the company’s business in Israel grows, they are tapping into the country’s innovative skills as well as meeting increased patient demand for a painless, non-invasive option for non-melanoma skin cancer and keloid treatment. Thousands of patients have already benefited from Sensus’s safe and effective technology, and Sheba Medical Center is pleased to make this treatment available to even more people.
